Healthcare giant Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals (J&J), will pay the federal government more than $2 billion in civil settlement and criminal fines to settle charges that Janssen Pharmaceuticals illegally marketed the blockbuster antipsychotic drug Risperdal.
“This is the largest civil criminal settlement in the history of the qui tam False Claims Act for a single drug,” says Stephen A. Sheller, founding partner of Sheller, P.C. in an interview with The American Law Journal.
According to Pro Publica, the whistleblower settlement is among the top five civil and criminal pharmaceutical company settlements in U.S. history and is the largest for a single drug. The settlement also includes the drug Invega®, which is a byproduct of Risperdal.